Stock Ratings / Health Care / KTTA / earnings

HIND (35) BOLT (28) LPCN (37) BIVI (33) ⌘ Pro Terminal →

Pasithea Therapeutics Corp. (KTTA) Next Earnings Date & Expected ±12.5% Move

$0.37 -5.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Pasithea Therapeutics Corp. (KTTA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $12.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KTTA)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.05 Expected Swing

MODEL EARNINGS SETUP GAUGE

KTTA Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$20.4M	-$15.2M	52%
FY 2024	2024-12-31	$0	-$13.9M	-$13.9M	52%
FY 2023	2023-12-31	$0	-$16.0M	-$14.4M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KTTA)

✓Walkthrough of KTTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KTTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.38%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.36H $0.39L $0.36C $0.37VOL 99.8K

RES: $0.48SUP: $0.33SMA50: $0.49SMA200: $0.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KTTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KTTA Butterfly Map → + Track KTTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KTTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KTTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KTTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KTTA)

Health Care Rank #525 of 1016 ⚔️ HIND vs KTTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KTTA vs. HIND, BOLT, LPCN, BIVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pasithea Therapeutics Corp. (KTTA) ranks #525 by composite RQD confidence (44/100, grade D) and #875 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, KTTA leads on earnings valuation at N/A trailing P/E, while KTTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KTTA ACTIVE Pasithea Therapeutics Corp.	D	44/100	—	—	-35.0%	-5.95%	$12.3M	Benchmark Subject
HIND Vyome Holdings Inc.	D-	35/100	—	68.4%	-35.0%	+1.74%	$12.3M	/hind-vs-ktta →
BOLT Bolt Biotherapeutics Inc.	E	28/100	—	—	-35.0%	-3.34%	$12.3M	/bolt-vs-ktta →
LPCN Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	/lpcn-vs-ktta →
BIVI BioVie Inc. (Class A)	E	33/100	—	—	-35.0%	-5.48%	$12.0M	/bivi-vs-ktta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001841330

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pasithea Therapeutics Corp. (KTTA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$20.4M, operating cash flow of -$15.2M, and free cash flow of -$15.2M (-9.3% YoY). On the balance sheet, KTTA closed FY2025 with $60.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$20.4M	-$15.2M	-$15.2M	$60.2M	—
FY2024 (FY)	2024-12-31	$0	-$13.9M	-$13.9M	-$13.9M	$16.1M	—
FY2023 (FY)	2023-12-31	$0	-$16.0M	—	—	—	—

3. KTTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KTTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Pasithea Therapeutics Corp. (NASDAQ: KTTA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.37 (-5.95% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KTTA ranks #525 in composite RQD confidence.

How does KTTA compare to HIND and BOLT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KTTA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and BOLT (Bolt Biotherapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, KTTA leads on earnings multiple (N/A) while KTTA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KTTA?

Per KTTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841330), Pasithea Therapeutics Corp. generated $0 in revenue, -$20.4M in net income, and -$15.2M in free cash flow against $60.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KTTA trading relative to its 50-day, 200-day, and 52-week technical levels?

KTTA last traded at $0.37 (-5.95% on volume of 329,816 shares), positioning the stock -24.49% below its 50-day simple moving average ($0.49) and -41.27% below its 200-day simple moving average ($0.63). Across its 52-week range of $0.28 to $2.06, KTTA sits at the 5.1% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).